Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 196

1.

Population-based screening for cancer: hope and hype.

Shieh Y, Eklund M, Sawaya GF, Black WC, Kramer BS, Esserman LJ.

Nat Rev Clin Oncol. 2016 Apr 13. doi: 10.1038/nrclinonc.2016.50. [Epub ahead of print] Review.

PMID:
27071351
2.

Lung cancer incidence and mortality in National Lung Screening Trial participants who underwent low-dose CT prevalence screening: a retrospective cohort analysis of a randomised, multicentre, diagnostic screening trial.

Patz EF Jr, Greco E, Gatsonis C, Pinsky P, Kramer BS, Aberle DR.

Lancet Oncol. 2016 Mar 18. pii: S1470-2045(15)00621-X. doi: 10.1016/S1470-2045(15)00621-X. [Epub ahead of print]

PMID:
27009070
3.

Reply to J. Cabezas et al.

Hwang JP, Somerfield MR, Alston-Johnson DE, Cryer DR, Feld JJ, Kramer BS, Sabichi AL, Wong SL, Artz AS.

J Clin Oncol. 2016 Jan 20;34(3):290-1. doi: 10.1200/JCO.2015.64.3064. Epub 2015 Dec 7. No abstract available.

PMID:
26644541
4.

Research Needs for Understanding the Biology of Overdiagnosis in Cancer Screening.

Srivastava S, Reid BJ, Ghosh S, Kramer BS.

J Cell Physiol. 2015 Oct 27. doi: 10.1002/jcp.25227. [Epub ahead of print] Review.

PMID:
26505642
5.

Lung Cancer Risk and Demographic Characteristics of Current 20-29 Pack-year Smokers: Implications for Screening.

Pinsky PF, Kramer BS.

J Natl Cancer Inst. 2015 Oct 19;107(11). pii: djv226. doi: 10.1093/jnci/djv226. Print 2015 Nov.

PMID:
26483244
6.

Predictive Value Tools as an Aid in Chemopreventive Agent Development.

Dunn BK, Steele VE, Fagerstrom RM, Topp CF, Ransohoff D, Cunningham C, Lubet R, Ford LG, Kramer BS.

J Natl Cancer Inst. 2015 Sep 28;107(12):djv259. doi: 10.1093/jnci/djv259. Print 2015 Dec.

PMID:
26420882
7.

Study designs for determining and comparing sensitivities of disease screening tests.

Prorok PC, Kramer BS, Miller AB.

J Med Screen. 2015 Dec;22(4):213-20. doi: 10.1177/0969141315600003. Epub 2015 Sep 22.

PMID:
26396138
8.

Latent class instrumental variables: a clinical and biostatistical perspective.

Baker SG, Kramer BS, Lindeman KS.

Stat Med. 2016 Jan 15;35(1):147-60. doi: 10.1002/sim.6612. Epub 2015 Aug 4.

PMID:
26239275
9.

Comprehensive Quality Management (CQM) in the PLCO Trial.

Gohagan JK, O'Brien B, Hasson MA, Umbel KD, Bridgeman B, Kramer BS, Reding D, Gren L, Wright P, Riley T, Prorok PC.

Rev Recent Clin Trials. 2015;10(3):223-32.

PMID:
26238118
10.

The PLCO Cancer Screening Trial: Background, Goals, Organization, Operations, Results.

Gohagan JK, Prorok PC, Greenwald P, Kramer BS.

Rev Recent Clin Trials. 2015;10(3):173-80.

PMID:
26238115
11.

Cancer Care Delivery Research: Building the Evidence Base to Support Practice Change in Community Oncology.

Kent EE, Mitchell SA, Castro KM, DeWalt DA, Kaluzny AD, Hautala JA, Grad O, Ballard RM, McCaskill-Stevens WJ, Kramer BS, Clauser SB.

J Clin Oncol. 2015 Aug 20;33(24):2705-11. doi: 10.1200/JCO.2014.60.6210. Epub 2015 Jul 20.

PMID:
26195715
12.

Evaluating Prognostic Markers Using Relative Utility Curves and Test Tradeoffs.

Baker SG, Kramer BS.

J Clin Oncol. 2015 Aug 10;33(23):2578-80. doi: 10.1200/JCO.2014.58.0092. Epub 2015 Jun 29. No abstract available.

PMID:
26124476
13.

Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update.

Hwang JP, Somerfield MR, Alston-Johnson DE, Cryer DR, Feld JJ, Kramer BS, Sabichi AL, Wong SL, Artz AS.

J Clin Oncol. 2015 Jul 1;33(19):2212-20. doi: 10.1200/JCO.2015.61.3745. Epub 2015 May 11.

PMID:
25964247
14.

Lung cancer risk by years since quitting in 30+ pack year smokers.

Pinsky PF, Zhu CS, Kramer BS.

J Med Screen. 2015 Sep;22(3):151-7. doi: 10.1177/0969141315579119. Epub 2015 Apr 29.

PMID:
25926339
15.

Projecting the benefits and harms of mammography using statistical models: proof or proofiness?

Kramer BS, Elmore JG.

J Natl Cancer Inst. 2015 Apr 29;107(7). pii: djv145. doi: 10.1093/jnci/djv145. Print 2015 Jul. No abstract available.

PMID:
25925581
16.

Colorectal cancer prevention and fishful thinking.

Umar A, Richmond E, Kramer BS.

J Natl Cancer Inst. 2015 Mar 25;107(4). pii: djv052. doi: 10.1093/jnci/djv052. Print 2015 Apr. No abstract available.

17.

JNCI and cancer prevention.

Dunn BK, Ghosh S, Kramer BS.

J Natl Cancer Inst. 2015 Feb 24;107(3). pii: djv021. doi: 10.1093/jnci/djv021. Print 2015 Mar.

18.

Leveraging biospecimen resources for discovery or validation of markers for early cancer detection.

Schully SD, Carrick DM, Mechanic LE, Srivastava S, Anderson GL, Baron JA, Berg CD, Cullen J, Diamandis EP, Doria-Rose VP, Goddard KA, Hankinson SE, Kushi LH, Larson EB, McShane LM, Schilsky RL, Shak S, Skates SJ, Urban N, Kramer BS, Khoury MJ, Ransohoff DF.

J Natl Cancer Inst. 2015 Feb 16;107(4). pii: djv012. doi: 10.1093/jnci/djv012. Print 2015 Apr.

19.

Conceptualizing overdiagnosis in cancer screening.

Marcus PM, Prorok PC, Miller AB, DeVoto EJ, Kramer BS.

J Natl Cancer Inst. 2015 Feb 6;107(4). pii: djv014. doi: 10.1093/jnci/djv014. Print 2015 Apr.

20.

Multilevel modeling and value of information in clinical trial decision support.

Cui Y, Murphy B, Gentilcore A, Sharma Y, Minasian LM, Kramer BS, Coates PM, Gohagan JK, Klenk J, Tidor B.

BMC Syst Biol. 2014 Dec 24;8:6. doi: 10.1186/s12918-014-0140-0.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk